

Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.
You can purchase shares of Ocular Therapeutix (NASDAQ:OCUL) through any online brokerage.
Other companies in Ocular Therapeutix’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Ocular Therapeutix has a consensus price target of $22.19.
The stock price for Ocular Therapeutix (NASDAQ: OCUL) is $7.3 last updated October 28, 2026 at 6:47 PM EDT.
There are no upcoming dividends for Ocular Therapeutix.
Ocular Therapeutix does not have any upcoming earnings scheduled.
There is no upcoming split for Ocular Therapeutix.
Ocular Therapeutix is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of...